表紙
市場調查報告書

水痘活疫苗全球市場預測 (2020∼2028年)

Global Varicella Live Vaccine Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 923543
出版日期 內容資訊 英文 169 Pages
商品交期: 2-3個工作天內
價格
水痘活疫苗全球市場預測 (2020∼2028年) Global Varicella Live Vaccine Market Forecast 2020-2028
出版日期: 2020年02月03日內容資訊: 英文 169 Pages
簡介

預估全球水痘活疫苗市場將於2020∼2028年以5.78%的CAGR成長。市場成長主要因素包含對於水痘疫苗使用的興趣提升、社會的快速滲透和接受、政府對預防接種程序的積極參與等。在區域方面,北美各國雖為最大市場,亞太地區市場也逐漸快速成長。

本報告研究全球錯誤追蹤軟體市場,彙整市場基本架構、主要推動和阻礙因素、市場規模趨勢展望 (未來9年),提供按企業規模、發展方式、產業、區域的詳細趨勢,以及市場競爭趨勢、主要企業簡介 (企業概要、主要產品/服務、業務策略等) 等情報。

第1章 研究範圍和方法

第2章 摘要整理

第3章 市場動態

  • 市場定義
  • 主要市場推動因素
    • 水痘活疫苗應用的意識提升
    • 預防接種程序中政府的積極參與
    • 水痘活疫苗的快速接受和滲透
  • 主要市場阻礙因素
    • 水痘疫苗的開發:費時的程序
    • 龐大的資本支出
    • 水痘活疫苗相關副作用

第4章 主要分析

  • 波特五力分析
    • 新參與企業的威脅
    • 替代品的威脅
    • 買方交涉力
    • 供應商交涉力
    • 企業間競爭
  • 監管框架
    • 美國疫苗相關監管要件和框架
    • 歐洲疫苗相關監管要件和框架
    • 亞太地區疫苗相關監管要件和框架
  • 水痘疫苗類型
  • 市場機會矩陣
  • 供應商情勢

第5章 按產品的市場

  • 單價水痘疫苗
  • 組合水痘疫苗

第6章 按應用的市場

  • 水痘疫苗的預防接種
  • 帶狀泡疹的預防接種
  • MMRV的預防接種

第7章 按提供商的市場

  • 民營提供商
  • 公營提供商

第8章 地理分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄國
    • 比利時
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲和紐西蘭
    • 韓國
    • 泰國
    • 印尼
    • 越南
    • 其他亞太地區國家
  • 其他國家 (RoW)
    • 拉丁美洲
    • 中東和非洲地區

第9章 企業簡介

  • BIO-MED PVT. LIMITED
  • CHANGCHUN BCHT BIOTECHNOLOGY CO. LTD.
  • GREEN CROSS HOLDINGS (GC PHARMA)
  • EMCURE PHARMACEUTICALS LIMITED (ZUVENTUS HEALTHCARE LTD.)
  • EMERGENT BIOSOLUTIONS INC.
  • GLAXOSMITHKLINE PLC
  • MERCK & CO. INC.
  • MITSUBISHI CHEMICAL HOLDINGS CORPORATION (MITSUBISHI TANABE PHARMA CORPORATION)
  • NOVAVAX INC.
  • NOVO MEDI SCIENCES PVT. LTD.
  • SANOFI
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 29368

KEY FINDINGS:

The global varicella live vaccine market is estimated to grow and record a CAGR of 5.78% during the forecast period of 2020-2028. The factors fueling the market growth are the rise in the awareness of varicella live vaccine usage, a major boost in the acceptance of varicella vaccines, and active participation of government in immunization programs.

MARKET INSIGHTS:

The varicella live vaccines help to build immunity against the varicella-zoster virus, which can cause serious diseases like chickenpox and herpes zoster. Immunization with varicella live vaccines is an effective method to prevent these diseases. These vaccines are categorized mainly in two types, such as combination and monovalent.

One of the important factors propelling market growth is a boost in immunization programs across the globe. Active government initiatives and continuous efforts to ensure immunization boosts the varicella live vaccine market growth. In addition, there is a soaring increase in awareness regarding the usage of varicella vaccines in developing countries like India, owing to the presence of programs that discuss vaccines and vaccination. However, high monetary inputs associated with the production of the product hinders the growth of the market. There is intense competition in the market among Merck & Co. Inc., Sanofi, and Takeda Pharmaceutical Company Limited, which are the major shareholders in the market.

REGIONAL INSIGHTS:

The global varicella live vaccine market is geographically analyzed on the basis of the markets situated across the regions of North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America accounted for the largest market share in terms of revenue and continues the trend towards the end of the projected period. This is attributed to the easy availability of the varicella vaccines and the presence of the leading companies in the market, among other factors.The Asia Pacific region is predicted to register the highest growth rate in terms of revenue.One of the primary reasons is a surge in the availability of improved healthcare services.

COMPETITIVE INSIGHTS:

Merck & Co., Inc., Bio-Med Pvt. Limited, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, etc. are some of the principal companies operating in the market which have a global presence.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARIES

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISE IN THE AWARENESS OF VARICELLA LIVE VACCINES USAGE
    • 3.2.2. ACTIVE PARTICIPATION OF GOVERNMENT IN IMMUNIZATION PROGRAMS
    • 3.2.3. SURGE IN THE ACCEPTANCE OF VARICELLA LIVE VACCINES
  • 3.3. KEY RESTRAINTS
    • 3.3.1. TIME-CONSUMING PROCESS FOR THE DEVELOPMENT OF VARICELLA LIVE VACCINE
    • 3.3.2. HUGE CAPITAL EXPENDITURES
    • 3.3.3. SIDE EFFECTS ASSOCIATED WITH THE VARICELLA LIVE VACCINE

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
    • 4.2.1. LEGAL REQUIREMENTS AND FRAMEWORK FOR VACCINES IN THE U.S.
    • 4.2.2. LEGAL REQUIREMENTS AND FRAMEWORK FOR VACCINES IN THE EUROPE
    • 4.2.3. LEGAL REQUIREMENTS AND FRAMEWORK FOR VACCINES IN THE ASIA-PACIFIC
  • 4.3. VARICELLA VACCINES ETYMOLOGY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE

5. MARKET BY PRODUCT

  • 5.1. MONOVALENT VARICELLA VACCINE
  • 5.2. COMBINATION VARICELLA VACCINE

6. MARKET BY APPLICATION

  • 6.1. CHICKENPOX IMMUNIZATION
  • 6.2. HERPES ZOSTER IMMUNIZATION
  • 6.3. MMRV IMMUNIZATION

7. MARKET BY PROVIDER

  • 7.1. PRIVATE PROVIDER
  • 7.2. PUBLIC PROVIDER

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. THE UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. THE UNITED KINGDOM
    • 8.2.2. FRANCE
    • 8.2.3. GERMANY
    • 8.2.4. ITALY
    • 8.2.5. RUSSIA
    • 8.2.6. BELGIUM
    • 8.2.7. POLAND
    • 8.2.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. INDIA
    • 8.3.4. AUSTRALIA & NEW ZEALAND
    • 8.3.5. SOUTH KOREA
    • 8.3.6. THAILAND
    • 8.3.7. INDONESIA
    • 8.3.8. VIETNAM
    • 8.3.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES

  • 9.1. BIO-MED PVT. LIMITED
  • 9.2. CHANGCHUN BCHT BIOTECHNOLOGY CO. LTD.
  • 9.3. GREEN CROSS HOLDINGS (GC PHARMA)
  • 9.4. EMCURE PHARMACEUTICALS LIMITED (ZUVENTUS HEALTHCARE LTD.)
  • 9.5. EMERGENT BIOSOLUTIONS INC.
  • 9.6. GLAXOSMITHKLINE PLC
  • 9.7. MERCK & CO. INC.
  • 9.8. MITSUBISHI CHEMICAL HOLDINGS CORPORATION (MITSUBISHI TANABE PHARMA CORPORATION)
  • 9.9. NOVAVAX INC.
  • 9.10. NOVO MEDI SCIENCES PVT. LTD.
  • 9.11. SANOFI
  • 9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - VARICELLA LIVE VACCINE
  • TABLE 2: GLOBAL VARICELLA LIVE VACCINE, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL VARICELLA LIVE VACCINE, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL VARICELLA LIVE VACCINE, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL VARICELLA LIVE VACCINE, BY APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL VARICELLA LIVE VACCINE, BY PROVIDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL VARICELLA LIVE VACCINE, BY PROVIDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL VARICELLA LIVE VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL VARICELLA LIVE VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA VARICELLA LIVE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: NORTH AMERICA VARICELLA LIVE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: EUROPE VARICELLA LIVE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: EUROPE VARICELLA LIVE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: ASIA PACIFIC VARICELLA LIVE VACCINE, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: ASIA PACIFIC VARICELLA LIVE VACCINE, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: REST OF WORLD VARICELLA LIVE VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: REST OF WORLD VARICELLA LIVE VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: GLOBAL VARICELLA LIVE VACCINE, BY PRODUCT, IN 2019
  • FIGURE 5: GLOBAL VARICELLA LIVE VACCINE MARKET, BY MONOVALENT VARICELLA VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 6: GLOBAL VARICELLA LIVE VACCINE MARKET, BY COMBINATION VARICELLA VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL VARICELLA LIVE VACCINE, BY APPLICATION, IN 2019
  • FIGURE 8: GLOBAL VARICELLA LIVE VACCINE MARKET, BY CHICKENPOX IMMUNIZATION, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL VARICELLA LIVE VACCINE MARKET, BY HERPES ZOSTER IMMUNIZATION, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL VARICELLA LIVE VACCINE MARKET, BY MMRV IMMUNIZATION, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL VARICELLA LIVE VACCINE, BY PROVIDER, IN 2019
  • FIGURE 12: GLOBAL VARICELLA LIVE VACCINE MARKET, BY PRIVATE PROVIDER, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL VARICELLA LIVE VACCINE MARKET, BY PUBLIC PROVIDER, 2020-2028 (IN $ MILLION)
  • FIGURE 14: NORTH AMERICA VARICELLA LIVE VACCINE MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 15: THE UNITED STATES VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 16: CANADA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 17: EUROPE VARICELLA LIVE VACCINE MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 18: THE UNITED KINGDOM VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: FRANCE VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 20: GERMANY VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: ITALY VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: RUSSIA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: BELGIUM VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: POLAND VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: REST OF EUROPE VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: ASIA PACIFIC VARICELLA LIVE VACCINE MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 27: CHINA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 28: JAPAN VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 29: INDIA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 30: AUSTRALIA & NEW ZEALAND VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 31: SOUTH KOREA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 32: THAILAND VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 33: INDONESIA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 34: VIETNAM VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 35: REST OF ASIA PACIFIC VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 36: REST OF WORLD VARICELLA LIVE VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 37: LATIN AMERICA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: MIDDLE EAST & AFRICA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)